Media / Science Center

Media/
Science Center

Videos

thumbnail image

Dr William Schmidt discusses how PF614 TAAP works – from the IASP World Congress 2024.

Dr William Schmidt discusses how PF614 TAAP works – from the IASP World Congress 2024Download Transcript
thumbnail image

Dr William Schmidt discusses the ideal analgesic profile – from the IASP World Congress 2024.

Dr William Schmidt discusses the ideal analgesic profile – from the IASP World Congress 2024Download Transcript
thumbnail image

Dr J Gudin discusses the ideal analgesic

Dr J Gudin discusses the ideal analgesicDownload Transcript
thumbnail image

Dr. Dart introducing MPAR overdose protection

Dr. Dart introducing MPAR overdose protectionDownload Transcript
thumbnail image

Pain Week 2023

Pain Week 2023Download Transcript

Podcasts

22:34

Drug Discovery World – Dr Lynn Kirkpatrick explains PF614-MPAR

Drug Discovery World – Dr Lynn Kirkpatrick explains PF614-MPARDownload Transcript
12:12

Stock Day Podcast – Dr. Lynn Kirkpatrick talks about TAAP, MPAR and pain relief products

Stock Day Podcast – Dr. Lynn Kirkpatrick talks about TAAP, MPAR and pain relief productsDownload Transcript

Abstracts & Manuscripts

March 2024
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.
Download PDF
February 2024
A Novel Trypsin Activated Abuse Protected (TAAP™) ER Oxycodone Prodrug with Overdose Protection
Download PDF
March 2024
Preventing Prescription Drug Overdoses, Clinical development of Trypsin-Activated Abuse Deterrent (TAAP) Opioids with Overdose Protection
Download PDF
October 2023
Development of an extended release nafamostat formulation for prescription drug overdose protection. 
Download PDF
September 2023
PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection. In: Symposium on Severe Pain, Next Generation Solutions – PF614 / PF614-MPAR. 
Download PDF
September 2023
PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection.
Download PDF
September 2023
Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Oxycodone Prodrug. 
Download PDF
September 2023
Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug.
Download PDF
July 2023
Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose.
Download PDF
June 2023
Intranasal Human Abuse Potential of PF614: A Novel ‘Next Generation’ Trypsin Activated Abuse Protected (TAAP) Opioid.
Download PDF
February 2023
MPAR: A Chemical Approach to Opioid Overdose Protection.
Download PDF
May 2022
The Next Generation Opioid Products for Moderate-Severe Pain
Download PDF
November 2019
Nonclinical Safety Assessment of PF614, a Novel TAAP Prodrug of Oxycodone
Download PDF
May 2017
First-in-human pharmacokinetics & safety study of PF614: orally activated oxycodone prodrug. 
Download PDF
May 2017
First-in-human pharmacokinetics & safety study of PF614, orally activated oxycodone prodrug
Download PDF
January 2017
In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone
Download PDF
2012
First in man evaluation of PF329
Download PDF